You're right and that's where it gets very interesting. My understanding is that the uptake of iPPS could be quite high using special access scheme mechanisms in the same way that other medications like Tranexamic acid (used to minimise blood loss in surgery) was prior to it's widened indication on the basis of trial data. We know the medication is safe, we know it works - there is very few in the physician/surgical fields that have yet heard of it and that will change quickly when data is published in journals, and even quicker than that when patients start asking for it directly.
In terms of trial risks there needs to be some credit given to the people who are already endorsing this therapy. They are very highly regarded in their fields, prominent clinicians and researchers with higher degrees and a great deal of experience conducting research in arthritis management. The trials themselves are really just the same as the data sets that are already taken on patients having arthritis treatment. Function and pain scores are well validated and there is little grey area for misinterpretation of data or biases. If you think of stocks like RAP that have a great product but are hindered by the problems of getting clinicians to agree on what constitutes positive and negative results and even agreeing on what defines a given respiratory condition - those problems aren't going to occur here.
Having a proven benefit in bone oedema management is just massive. There is even a hint in the recent results showing improvement in soft tissues around the affected region (the achilles tendon MRI pre and post shows real change and remodeling) and I have no doubt that they are telling us there that there is a likely indication for soft tissue inflammation and tendinopathy.
If you think of all the Physios/Orthos/Rheumatologists that will jump on this with trials the data will come hard and fast once it starts. The other side of this is that the share price will appreciate quickly once they become aware of the opportunity to invest. It will be similar to Cochlear, it's hard to find an ENT surgeon who hasn't owned shares at some stage.
I thought i'd bought my fill but likely to get more if the price stays near it's current levels.
PAR Price at posting:
$1.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)